Benzodiazepines Reduce Cancer Immunotherapy Success in 50,000+ Lung Cancer Patients
Nationwide French study reveals benzodiazepine use significantly worsens survival outcomes in lung cancer patients receiving pembrolizumab immunotherapy.
Summary
A massive French study of over 50,000 lung cancer patients found that benzodiazepine use significantly reduces the effectiveness of pembrolizumab immunotherapy. Patients taking benzodiazepines had 8% higher risk of death and showed signs of gut microbiome disruption that may interfere with immune response. This suggests common anxiety medications could undermine cancer treatment success through effects on the gut-immune axis.
Detailed Summary
This groundbreaking nationwide French study analyzed over 50,000 advanced lung cancer patients to investigate whether benzodiazepines interfere with cancer immunotherapy effectiveness. The research builds on previous findings that diazepam binding inhibitor (DBI), an endogenous compound that mimics benzodiazepine effects, may promote cancer development and reduce immune surveillance.
Researchers examined 31,479 eligible patients who survived at least 2 months after starting pembrolizumab treatment. Of these, 37.7% (11,878 patients) received at least two benzodiazepine prescriptions within the treatment window. The results were striking: benzodiazepine users had significantly reduced overall survival with an 8% increased risk of death (hazard ratio 1.08, p<0.001) compared to non-users.
Crucially, this effect persisted even after sophisticated statistical adjustments for age, cancer stage, other medications, and socioeconomic factors using inverse probability weighting. In a subset of 556 patients from the ONCOBIOTICS study, benzodiazepine use was associated with intestinal dysbiosis and alterations in the TOPOSCORE—a prognostic marker linked to poorer immunotherapy outcomes.
The findings suggest benzodiazepines may impair cancer immunotherapy through multiple mechanisms: direct effects on immune cell function via GABA receptors, disruption of the gut microbiome that's crucial for immunotherapy response, and elevation of stress hormones that suppress immune function. This represents the largest study to date examining this drug-immunotherapy interaction, with implications for millions of cancer patients worldwide who use these common anxiety medications.
Key Findings
- 37.7% of 31,479 lung cancer patients (11,878 individuals) used benzodiazepines during pembrolizumab treatment
- Benzodiazepine users had 8% increased risk of death (hazard ratio 1.08, 95% CI: 1.04-1.12, p<0.001)
- Survival disadvantage persisted after adjusting for demographics, cancer stage, and other medications using inverse probability weighting
- Benzodiazepine use associated with intestinal dysbiosis in subset of 556 patients from ONCOBIOTICS study
- Users showed alterations in TOPOSCORE, a validated prognostic marker for immunotherapy outcomes
- Effect remained significant across multiple statistical models and sensitivity analyses
- Study represents largest cohort to date examining benzodiazepine-immunotherapy interactions
Methodology
Retrospective analysis of French national registry data for advanced NSCLC patients treated with pembrolizumab between 2017-2021. Primary endpoint was overall survival, with benzodiazepine exposure defined as ≥2 prescriptions within 90 days before to 30 days after treatment initiation. Statistical analysis used Cox proportional hazards models with inverse probability of treatment weighting (IPTW) to control for confounding variables including age, performance status, cancer stage, and comedications.
Study Limitations
Retrospective observational design cannot establish causation, only association. Benzodiazepine dosing and duration data were limited. Potential unmeasured confounding factors like anxiety severity or underlying health conditions that prompt benzodiazepine use. Microbiome analysis was limited to a small subset of patients. Authors note need for prospective trials to confirm whether benzodiazepine withdrawal improves immunotherapy outcomes.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.